Clinical Research Directory
Browse clinical research sites, groups, and studies.
Dupixent Study for Alternate Administration
Sponsor: Madigan Army Medical Center
Summary
Investigators will investigate an alternate Dupilumab administration schedule in patients with recurrent chronic rhinosinusitis with nasal polyposis, who have a history of full endoscopic sinus surgery and are on appropriate topical medical therapies. Specifically, investigators will investigate if the alternate schedule of drug administration is non-inferior in both subjective and objective outcomes.
Official title: Efficacy of Alternate Dupilumab Schedule in Recurrent Chronic Rhinosinusitis With Nasal Polyposis Patients
Key Details
Gender
All
Age Range
18 Years - 100 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2021-10-14
Completion Date
2025-12
Last Updated
2025-01-17
Healthy Volunteers
Yes
Conditions
Interventions
Dupilumab
Dupilumab is an anti-IL 4-13 biologic therapy that has been recently approved for use in recurrent chronic rhinosinusitis with nasal polyposis.
Locations (1)
Madigan Army Medical Center
Tacoma, Washington, United States